GSK has agreed to acquire biotech Aiolos Bio for a $1 billion upfront payment and up to $400 million for the achievement of certain milestones. Founded just last year...

GSK has struck a deal with Chongqing Zhifei Biological Products to promote the British group's shingles vaccine, Shingrix, in China for an initial three-year period...

Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some...

European NGOs have welcomed the EU’s plans for an overhaul of pharmaceutical legislation – the first in two decades – presented this week in Brussels. The drugs industry...

GSK is set to gain exclusive rights to first-in-class oral antifungal Brexafemme (ibrexafungerp) for treating vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC) from...

As part of what seems to be a general pattern of staff reductions in the pharmaceutical industry worldwide, a growing number of Western drugmakers are downsizing their...

GSK is pruning its cooperation with Vir Biotechnology, turning away from Covid-19 antibody and vaccine research projects while continuing to collaborate with the company...

German biotech CureVac has released preliminary data from its ongoing cooperation with UK drugmaker GSK on a new class of “transformative medicines” based on messenger...